Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — FY 2024/25 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, Nov 4, 2025
Slide 1: Making life easier
Conference call presentation FY 2024/25 Making life easier Impact4: Setting the standard of care at scale Fabrizio | User, Continence Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: FY 2024/25 financial result
FY 2024/25 financial result Organic Reported Adjusted ROIC growth EBIT margin 7% 28% * * 15% ** *before special items Dorote | User, Continence Care **after tax and before special items. Adjusted for extraordinary tax impact from the transfer of Kerecis’ Intellectual Property to Denmark 3
Slide 4: Value creation during Impact4 will be measured through revenue and EBIT growth, as well as ROIC improvement
Value creation during Impact4 will be measured through revenue and EBIT growth, as well as ROIC improvement 2030 Financial ambition: 1 2 Organic revenue EBIT growth1 in line growth of 7-8% with or above revenue (5-year CAGR) growth over the period 3 Return on Invested Capital of more than 20% in FY
Slide 5: FY 2024/25 organic growth of 7% driven by Chronic Care, limited contribution from Interventional Urology
FY 2024/25 organic growth of 7% driven by Chronic Care, limited contribution from Interventional Urology due to product recall FY 2024/25 revenue by business area FY 2024/25 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Shar
Slide 6: FY 2024/25 reported revenue grew 3%, with ~1%-point detraction from divestment and currencies
FY 2024/25 reported revenue grew 3%, with ~1%-point detraction from divestment and ~2%-points negative impact from currencies FY 2024/25 Revenue development (mDKK) FY 2024/25 highlights • Reported revenue increased by DKK 844 million or 3% vs. last year. • Organic growth was 7% or DKK 1,784 million,
Slide 7: Reported EBIT margin was 28% in FY 2024/25 and includes ~30bps benefit from the Skin Care divestment
Reported EBIT margin was 28%1 in FY 2024/25 and includes ~30bps benefit from the Skin Care divestment FY 2024/25 EBIT margin development before special items (%) FY 2024/25 highlights • Gross margin was 68%, on par with last year. • Positive impact from a favourable development in input costs, price
Slide 8: Adjusted FCF was DKK 5,202 million in FY 2024/25, with a FCF-to-sales ratio of 19%
Adjusted FCF was DKK 5,202 million in FY 2024/25, with a FCF-to- sales ratio of 19% FCF development1 FY 2024/25 highlights • Free cash flow for FY 2024/25 was an inflow of DKK 5,394 million, 90 93 compared to an inflow of DKK 1,430 million last year. Last year’s FCF was 84 81 82 77 impacted by the t
Slide 9: FY 2025/26: Organic growth of ~7% and EBIT growth of ~7%. ROIC expected around 16%
FY 2025/26: Organic growth of ~7% and EBIT growth* of ~7%. ROIC** expected around 16%, or 1%-point improvement vs. last year Organic revenue growth Around 7% Reported revenue growth in DKK 4-5% EBIT growth* Around 7% ROIC** Around 16% Capex-to-sales ratio Around 5% Effective tax rate Around 22% *In
Slide 10: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding